Newsletter - View InhalteNewsletter2023

ID	6302
Newsletter2023	2026-02-17
Element	12855
Info	[Universal 2023] [Teaser] Arzneimittel-News Hauptbeitrag (27.01.2026) (12855)
Position	5
html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;font-size:0"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/2026q1/newsletter_2026-01-27_g2.jpg" alt="DAP Arzneimittel-News Hauptbeitrag" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="DAP Arzneimittel-News Hauptbeitrag"></td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">AKTUELLES</h3> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:28px;color:#005CA9">Teplizumab: ein Meilenstein in der Immuntherapie bei Typ-1-Diabetes</h2> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:18px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Mit Teplizumab ist es zum ersten Mal möglich, den Verlauf des Typ-1-Diabetes bereits vor dem eigentlichen Ausbruch gezielt zu beeinflussen. Damit verschiebt sich der therapeutische Ansatz von der reinen Behandlung der Folgen hin zu einer frühen Beeinflussung der Krankheitsursache. Im Januar hat die EU-Kommission dem monoklonalen Antikörper Teplizumab (Teizeild<sup style="line-height:0;">®</sup>) der Firma Sanofi die Zulassung erteilt.</p> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a target="_blank" href="https://www.deutschesapothekenportal.de/rezept-retax/nachrichten/arzneimittel/detail/teplizumab-ein-meilenstein-in-der-immuntherapie-bei-typ-1-diabetes/" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Lesen Sie hier weiter</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: Africa Studio – stock.adobe.com</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

Newsletter2023

2026-02-17

Info

[Universal 2023] [Teaser] Arzneimittel-News Hauptbeitrag (27.01.2026) (12855)

html

<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important">
    <tbody>
        <tr>
            <td align="center" style="padding:0;Margin:0">
                <table class="es-content-body" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center">
                    <tbody>
                        <tr>
                            <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px">
                                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                                    <tbody>
                                        <tr>
                                            <td valign="top" align="center" style="padding:0;Margin:0;width:660px">
                                                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff">
                                                    <tbody>
                                                        <tr>
                                                            <td align="left" style="padding:0;Margin:0;font-size:0"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/2026q1/newsletter_2026-01-27_g2.jpg" alt="DAP Arzneimittel-News Hauptbeitrag" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="DAP Arzneimittel-News Hauptbeitrag"></td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px">
                                                                <h3 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:14px;font-style:normal;font-weight:bold;line-height:18px;color:#555555">AKTUELLES</h3>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:10px;padding-bottom:0px">
                                                                <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:28px;color:#005CA9">Teplizumab: ein Meilenstein in der Immuntherapie bei Typ-1-Diabetes</h2>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" style="Margin:0;padding-right:20px;padding-bottom:0px;padding-left:20px;padding-top:18px">
                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px !important;letter-spacing:0;color:#555555;font-size:14px">Mit Teplizumab ist es zum ersten Mal möglich, den Verlauf des Typ-1-Diabetes bereits vor dem eigentlichen Ausbruch gezielt zu beeinflussen. Damit verschiebt sich der therapeutische Ansatz von der reinen Behandlung der Folgen hin zu einer frühen Beeinflussung der Krankheitsursache. Im Januar hat die EU-Kommission dem monoklonalen Antikörper Teplizumab (Teizeild<sup style="line-height:0;">®</sup>) der Firma Sanofi die Zulassung erteilt.</p>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;">
                                                                <table role="presentation" border="0" cellspacing="0" cellpadding="0">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td align="center" style="border-radius: 0px;" bgcolor="#005CA9">
                                                                                <a target="_blank" href="https://www.deutschesapothekenportal.de/rezept-retax/nachrichten/arzneimittel/detail/teplizumab-ein-meilenstein-in-der-immuntherapie-bei-typ-1-diabetes/" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Lesen Sie hier weiter</a>
                                                                            </td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0">
                                                                <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" style="Margin:0;padding-right:20px;padding-bottom:10px;padding-left:20px;padding-top:10px">
                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:13px;letter-spacing:0;color:#555555;font-size:11px">Bildquelle: Africa Studio – stock.adobe.com</p>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </td>
        </tr>
    </tbody>
</table>

View InhalteNewsletter2023 #6302